About: Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $27.67 (-3.17%)
AMLX NASDAQ Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc share price
Atividade de preço de AMLX
Último preço
$ 27,670
Variação (24h)
-0,91 USD (3,17%)
Volume
318.97K
Volume (média 4 sem.)
-
Abertura
$ 28,46
Variação do dia
$ 27,62 - $ 28,46
Fechamento anterior
$ 28,57
Último negócio
23 Oct, 3:24 pm GMT+0
Atrasado
23 Oct, 3:24 pm GMT+0
AMLX price performance
Atrasado
23 Oct, 3:24 pm GMT+0
quote.marketSignals